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Abstract 
New approaches to treat bacterial infections are badly needed to address the increasing problem 
of antibiotic-resistance. This study explores phosphonium-functionalized block copolymer 
micelles as intrinsically antibacterial polymer assemblies. Phosphonium cations with varying 
alkyl lengths were conjugated to the terminus of a poly(ethylene oxide)-polycaprolactone block 
copolymer and the phosphonium-functionalized block copolymers were self-assembled to form 
micelles in aqueous solution. The size, morphology, and z-potential of the assemblies were 
studied and their abilities to kill Escherichia coli and Staphylococcus aureus were evaluated. It 
was found that the minimum bactericidal concentration depended on the phosphonium alkyl 
chain length and different trends were observed for Gram-negative and Gram-positive bacteria. 
The most active assemblies exhibited no hemolysis of red blood cells above the bactericidal 
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concentrations, indicating that they can selectively disrupt the membranes of bacteria. 
Furthermore, it was possible to encapsulate and release the antibiotic tetracycline using the 
assemblies, providing a potential multi-mechanistic approach to bacterial killing.  
Keywords 
Phosphonium, antibacterial, micelles, antibiotic, self-assembly 
 
Introduction 
Polymeric nanocarriers, self-assembled nanoscopic materials with domains of different 
hydrophilicity, have been extensively investigated due to their abilities to encapsulate 
biomedically relevant cargo and to provide a chemically tunable platform.1–4 Common 
nanocarrier morphologies are spherical micelles5, cylindrical micelles,6,7 bilayer structures (e.g. 
vesicles)8 and in some circumstances more complex architectures that can be obtained using 
unconventional polymers or intermolecular interactions.9 Amphiphilic block copolymers are 
often the structural components of polymeric nanocarriers, due to the control they provide over 
the morphology and the well-established chemistry used to synthesize and functionalize them. 
By encapsulating hydrophobic compounds into the hydrophobic domains of nanomaterials, these 
water-insoluble molecules can be dispersed in aqueous solutions.4,10,11 Block copolymer 
nanocarriers have been and continue to be investigated for the delivery of a large variety of 
compounds including small molecule drugs, therapeutic nucleic acids, imaging contrast agents, 
and antibacterial compounds.1,4,12  
An increase in the occurrence of pernicious antibiotic resistant bacteria is currently 
motivating a search for novel ways of combating bacterial infections. The World Health 
Organization warns that in order to avoid a return to the “pre-antibiotic” age, researchers and 
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health professionals need to employ new and varied antibiotic treatments of bacterial 
infections.13 The ability to incorporate hydrophobic antibacterial compounds into aqueous 
dispersible nanocarriers allows for increased availability of the drugs at the site of infection.14 
The use of nanocarriers has allowed researchers to utilize traditional antibacterial compounds 
with improved efficacy. For example, intracellular bacterial infections are often resistant to 
antibacterial treatment due to the localization of the bacteria in the eukaryotic cells. Maya and 
coworkers were able to target intracellular Staphylococcus aureus (S. aureus) by encapsulating 
tetracycline in chitosan nanoparticles.15 Li et al. demonstrated the encapsulation of antibacterial 
agents into polymer vesicles that enzymatically degraded in the presence of target bacteria to 
deliver the antibacterial cargo.16 Furthermore, Liu and coworkers have recently demonstrated the 
ability of triclosan-loaded micelles to penetrate into biofilms and to kill the S. aureus residing in 
the biofilms with greater efficacy than free triclosan.17 There are many other examples that 
demonstrate the increase in desirable properties that can be achieved by loading antibacterial 
small molecules into nanocarrier systems.12,18,19 This approach may also allow for the use new 
poorly water-soluble antibacterial compounds in the combat of antibacterial resistance. 
Far fewer examples exist of nanocarriers with inherently antibacterial units. This is 
somewhat surprising given the extensive research that has been performed on incorporating 
functionality into nanocarrier design.2,20 The incorporation of silver nanoparticles21–23 and/or 
polymers such as chitosan24,25 or other polyammonium cations,26–29, have been explored as an 
approach for imparting antibacterial activity to nanocarriers. Previously unexplored is the use of 
phosphonium cations to impart antibacterial activity to polymeric nanocarriers. Phosphonium 
cations, like ammonium cations, are thought to interact with the negatively charged structural 
biopolymers and phospholipids on the outer surfaces of bacteria cell walls, leading to penetration 
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of the cell wall, ultimately resulting in cell death.29–31 Gram-positive bacteria such as S. aureus 
have teichoic acid polymers on the cell wall that confer a negative charge and Gram-negative 
bacteria such as Escherichia coli (E. coli) have lipopolyssacharides that are responsible for the 
negative charge of the cell surface. Previous research has demonstrated that phosphonium salts 
as well as their corresponding polymers exhibit improved antibacterial efficacy compared to 
analogous ammonium compounds.32–34 This can arise from the differences in charge distribution 
between the larger phosphonium cation and smaller ammonium cation. In this context, we 
recently demonstrated the efficacy of surfaces and semi-interpenetrating networks containing 
phosphonium cations against Gram-positive and Gram-negative bacteria.35,36 
Here we explore the synthesis and self-assembly of phosphonium end-capped poly(ethylene 
oxide)-block-polycaprolactone (PEO-b-PCL) copolymers. To the best of our knowledge, this 
represents the first example of phosphonium-functionalized block copolymer assemblies in 
aqueous solution. We also demonstrate the antibacterial properties of the assemblies against S. 
aureus and E. coli. Furthermore, it is shown that the antibiotic tetracycline can be incorporated 
into the micelles, potentially providing orthogonal modes of action, where the traditional 
antibiotic targets specific pathways in bacteria while the phosphonium cation provides 
membrane disruption (Figure 1). While work exists demonstrating the benefit of combining 
antibacterial nanoparticles with traditional antibacterial small molecules25,37 the deliberate 
encapsulation of a traditional antibacterial agent within an intrinsically antibacterial polymeric 
nanocarrier has not been reported. 
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Figure 1. Schematic illustrating a phosphonium-functionalized micelle loaded with antibiotic. 
Experimental 
General procedures and materials 
Methoxy and azide-terminated block copolymers (MeO-BCP and N3-BCP respectively) were 
prepared as previously reported38 and the characterization data for the specific batches used in 
the current work are included in the supporting information. Briefly, they were prepared by ring-
opening polymerizations of freshly distilled ε-caprolactone in dry toluene initiated by PEO 
monomethyl ether (MeO-PEO) or PEO monoazide (N3-PEO). Methanesulfonic acid was used 
as a catalyst, and the product was obtained by precipitation into cold hexanes. Solvents were 
dried using an MBraun Solvent Purification System. Dried solvent was collected under vacuum 
in a flame-dried Straus flask and stored over 4Å molecular sieves. Purified water was obtained 
using a BarnsteadTM EASYPure® II ultra pure water system (ThermoFisher Scientific). Nuclear 
Magnetic Resonance (NMR) spectroscopy was conducted on a Varian INOVA 400 MHz 
spectrometer (Agilent Technologies, Santa Clara, CA; 1H 400 MHz, 31P{1H} 162 MHz, 13C{1H} 
100 MHz) unless otherwise noted. All 1H NMR spectra were referenced relative to the residual 
solvent peak (CHCl3; 1H δ = 7.27). The chemical shifts for 31P{1H} NMR spectroscopy were 
referenced using an external standard (85% H3PO4; δP = 0). All 13C{1H} NMR spectra were 
referenced relative to the residual solvent peak (CDCl3; 13C δ = 77.0). Infrared (IR) spectra were 
obtained using a Bruker Tensor 27 spectrometer using attenuated total internal reflectance mode 
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(ATR) on a ZnSe crystal. High Resolution Mass spectrometry (HRMS) were obtained on a 
Finnigan MAT 8400 mass spectrometer using electron impact ionization. Dynamic light 
scattering (DLS) and z-potential measurements were performed on a Zetsizer Nano ZS from 
Malvern Instruments equipped with a 633 nm laser. A polymer concentration of ~0.1 mg/mL of 
polymer were used in DLS measurements. Ultraviolet-visible  (UV-vis) spectroscopy was 
performed using a Varian Cary 300 Bio UV-visible spectrophotometer. The size exclusion 
chromatography (SEC) instrument was equipped with a Viscotek GPC Max VE2001 solvent 
module (Malvern Instruments Ltd., Malvern, UK). Samples were analyzed using the Viscotek 
VE3580 RI detector operating at 30 °C. The separation technique employed two Agilent 
Polypore (300 × 7.5 mm) columns connected in series and to a Polypore guard column (50 × 7.5 
mm) (Agilent Technologies). Samples were dissolved in tetrahydrofuran (THF) (glass distilled 
grade) at a concentration of approximately 5 mg/mL, filtered through 0.22 µm syringe filters, and 
then injected using a 100 µL loop. The THF eluent was filtered and eluted at 1 mL/min for a total 
of 30 min. The instrument was calibrated with PEO standards. Dialysis was performed using 
Spectra/Por® 6 pre-wetted dialysis tubing (Spectrum Laboratories Inc.). 
 
Synthesis of tri-n-butyl(1-pentynyl)phosphonium chloride (Bu3P-yne) 
Tributylphosphine (5.00 g, 24.5 mmol, 1.0 equiv.) was dissolved in dry CH3CN in a pressure 
tube inside a glovebox. 5-Chloro-1-pentyne (2.80 g, 27.3 mmol, 1.1 equiv.) was then added 
dropwise to the stirring phosphine solution. The pressure tube was sealed and then heated at 100 
°C. The reaction was monitored by 31P{1H} NMR spectroscopy. Upon exhaustion of the tributyl 
phosphine the volatile components were removed in vacuo. The crude product was dissolved in 
CH2Cl2 and precipitated into a rapidly stirring solution of cold hexanes (0 °C) to afford an off-
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white powder. The product was recovered by vacuum filtration. Yield = 6.31 g, 84%. 1H NMR 
(400 MHz, CDCl3): δ = 2.70 – 2.68 (m, 2H), 2.53 – 2.42 (m, 8H), 2.05 (t, 4J(H,H) = 2.73 Hz, 
1H), 1.90 – 1.79 (m, 2H), 1.61 – 1.47 (m, 12H), 0.97 (t, 3J(H,H) = 7.23 Hz, 9H). 13C{1H} 
(100.52 MHz, CDCl3): δ = 82.0, 70.5, 23.9 (d, 3J(P,C) = 15.3 Hz), 23.7 (d, 2J(P,C) = 5.3 Hz), 
21.0 (d, 2J(P,C) = 3.8 Hz), 19.4 (d, 3J(P,C) = 16.8 Hz), 19.0 (d, 1J(P,C) = 47.5 Hz), 18.2 (d, 
1J(P,C) = 49.0 Hz), 13.4. 31P{1H} NMR (161.82 MHz, CDCl3): δ = 34. ATR-IR: 2105 cm-1 (w, 
C≡C-H), 2960 cm-1 (s, CH). HRMS calculated for C17H34P [M]+: 269.2398; Found: 269.2400. 
 
Synthesis of triethyl(1-pentynyl)phosphonium chloride (Et3P-yne) 
The same procedure described above for the synthesis of Bu3P-yne was used except that 
triethylphosphine was used as the starting material.  The product was obtained as a light brown 
powder. Yield = 80%. 1H NMR (400 MHz, CDCl3): δ = 2.62 – 2.47 (m, 8H), 2.41 (ddt, 3J(H,H) 
= 3.6 Hz, 4J(H,H) = 2.7 Hz, 4J(P,H) = 0.8 Hz, 2H), 2.02 (t, 4J(H,H) = 2.7 Hz, 1H), 1.87 – 1.77 
(m, 2H), 1.28 (dt, 3J(H,H) = 7.6 Hz, 3J(P,H) = 18.0 Hz, 9H). 13C{1H} (100.52 MHz, CDCl3): δ = 
82.1, 70.9, 21.0 (d, 2J(P,C) = 3.7 Hz), 19.6 (d, 3J(P,C) = 16.5 Hz), 17.1 (d, 1J(P,C) = 48.6 Hz), 
12.5 (d, 1J(P,C) = 48.7 Hz), 6.2 (d, 2J(P,C) = 5.5 Hz). 31P{1H} NMR (161.82 MHz, CDCl3): δ = 
39. ATR-IR: 2105 cm-1 (w, C≡C-H), 2960 cm-1 (s, CH). HRMS calculated for C11H21P [M]+: 
184.1381; Found: 184.1379. 
 
Synthesis of tri-n-octyl(1-pentynyl)phosphonium chloride (Oct3P-yne) 
Tri-n-octylphosphine (1.00 g, 2.70 mmol, 1.0 equiv.) was dissolved in dry dioxane in a pressure 
tube inside a glovebox. 5 mg of NaI was added to the reaction mixture. 5-Chloro-1-pentyne 
(0.300 g, 2.92 mmol, 1.1 equiv.) was then added dropwise to the stirring phosphine solution. The 
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pressure tube was sealed and then heated at 100 °C. The reaction was monitored by 31P{1H} 
NMR spectroscopy. At approximately 50% conversion of the starting phosphine, the excess 
phosphine, 5-chloropentyne and solvent were removed in vacuo. The resulting colourless oil was 
washed twice with excess hexanes. The crude product was purified on a silica gel column using 
1:1 CH2Cl2:MeOH as the eluent. Fractions were checked for purity by 31P{1H} NMR 
spectroscopy, pure fractions were combined and the solvent was removed in vacuo to provide a 
light brown viscous oil. Yield = 12%. 1H NMR (400 MHz, CDCl3): δ = 2.70 – 2.57 (m, 2H), 
2.44 – 2.34 (m, 8H), 2.00 (t, 4J(H,H) = 2.6 Hz, 1H), 1.84 – 1.76 (m, 2H), 1.54 – 1.41 (m, 12H), 
1.27 – 1.22 (m, 24H), 0.83 (t, 3J(H,H) = 6.8 Hz, 9H). 13C{1H} (100.52 MHz, CDCl3): δ = 81.9, 
70.4, 31.5, 30.7 (d, 1J(P,C) = 14.1 Hz), 28.8, 22.4, 21.7 (d, 3J(P,C) = 4.0 Hz), 21.0 (d, 3J(P,C) = 
4.0 Hz), 19.3 (d, 1J(P,C) = 17.1 Hz), 19.2 (d, 2J(P,C) = 46.2 Hz), 18.2 (d, 2J(C,H) = 49.2 Hz), 
13.9 (s, CH3). 31P{1H} NMR (161.82 MHz, CDCl3): δ = 33.9. ATR-IR: 1460 cm-1 (m, P-CnHm), 
2120 cm-1 (w, C≡C-H), 2920 cm-1 (s, CH). HRMS calculated for C29H58P [M]+: 437.4276; 
Found: 437.4267. 
 
Synthesis of Alk3P-BCP 
N3-BCP (100 mg, 21 µmol, 1 equiv.) was suspended in purified water (2 mL) with stirring. The 
trialkyl(1-pentynyl)phosphonium chloride (42 µmol, 2.0 equiv) as a solution in THF (0.5 mL), 
and Cu(II)Cl2 (4 mg, 23 µmol, 1 equiv.) were added. A 50 mM aqueous solution of sodium 
ascorbate (2 mL, 210 µmol, 10 equiv.) was added with rapid stirring and the reaction flask was 
sealed. After 18 hours, the reaction mixture was dialyzed using a 10 kg/mol molecular weight 
cut-off (MWCO) membrane first against 1 L of a 0.5 mM aqueous NaCl solution for 18 hours, 
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then against 1 L of purified water for 12 hours twice. The sample was then lyophilized to obtain 
the phosphonium-functionalized polymer as a white powder in approximately quantitative yield. 
Et3P-BCP: 1H NMR (400 MHz, CDCl3): 7.70 (s, 1H), 4.50 (t, 3J(H,H) = 4.9 Hz, 2H), 4.02 (t, 
3J(H,H) = 6.6 Hz, 52H), 3.60 (m, 180H), 2.90 (t, 3J(H,H) = 6.4 Hz, 2H), 2.49 (dq, 2J(H,P) = 13.0 
Hz, 3J(H,H) = 8 Hz, 6H); 2.29 (t, 3J(H,H) = 7.6 Hz, 52H), 1.66-1.56 (m, 104H), 1.40 – 1.30 (m, 
52H), 1.25 (dt, 3J(H,P) = 18.0 Hz, 3J(H,H) = 7.6 Hz, 9H). 31P{1H} NMR (161.82 MHz, CDCl3): 
δ = 38.7. ATR-IR: 1105 cm-1 (m, CH2-O-CH2); 1190 cm-1 (m, O-C=O); 1720 cm-1 (s, C=O); 
2800 – 2900 cm-1 (m, C-H). 
Bu3P-BCP: 1H NMR (400 MHz, CDCl3): δ = 7.72 (s, 1H); 4.50 (t, 3J(H,H) = 5.2 Hz, 2H), 4.03 
(t, 3J(H,H) = 6.6 Hz, 52H), 3.61 (m, 180H), 2.90 (m, 2H), 2.65 (m, 2H), 2.37 (m, 8H), 2.27 (t, 
3J(H,H) = 7.6 Hz, 52H), 1.66-1.56 (m, 104H), 1.48 (m, 12H), 1.40 – 1.30 (m, 52H), 0.94 (t, 
3J(H,H) = 6.4 Hz). 31P{1H} NMR (161.82 MHz, CDCl3); δ = 33.3. ATR-IR: 1105 cm-1 (m, CH2-
O-CH2); 1190 cm-1 (m, O-C=O); 1720 cm-1 (s, C=O); 2800 – 2900 cm-1 (m, C-H). 
Oct3P-BCP: 1H NMR (400 MHz, CDCl3): δ = 7.72 (s, 1H), 4.50 (t, 3J(H,H) = 5.2 Hz, 2H), 4.03 
(t, 3J(H,H) = 6.6 Hz, 52H), 3.61 (m, 180H), 2.90 (m, 2H), 2.65 (m, 2H), 2.37 (m, 8H), 2.27 (t, 
3J(H,H) = 7.6 Hz, 52H), 1.66-1.56 (m, 104H), 1.48 (m, 12H), 1.40 – 1.30 (m, 52H); 0.94 (t, 
3J(H,H) = 6.4 Hz, 20H). 31P{1H} NMR (161.82 MHz, CDCl3); δ = 33.3. ATR-IR: 1105 cm-1 (m, 
CH2-O-CH2); 1190 cm-1 (m, O-C=O); 1720 cm-1 (s, C=O); 2800 – 2900 cm-1 (m, C-H). 
 
Self-assembly of block copolymers 
Copolymer (5 mg) was dissolved in glass distilled THF (0.5 mL) that had been passed through a 
0.22 μm polytetrafluoroethylene filter. The copolymer solution was then added to rapidly stirring 
purified water (2 mL) that had been passed through an Acrodisc® Syringe Filter (0.45 µm 
 10 
Supor® Membrane) (Pall Life Sciences). The resulting suspension was placed in a 30 °C sand 
bath overnight to evaporate the THF.  
 
Transmission electron microscopy (TEM) 
TEM images were obtained using a Philips CM 10 Transmission Electron Microscope. Self-
assembly samples were loaded onto Formvar-coated copper grids by placing the grid on a clean 
filter paper and dropping 10 µL of a 0.5 – 1.0 mg/mL solution onto the grid, and repeating after 
30 seconds. The grid was allowed to dry overnight on the filter paper and was imaged the next 
day. The Alk3P-BCP nanocarriers were stained by adding 100 μL of a 1 wt% aqueous auric acid 
solution to the stock TEM solution and allowing it to stir for one hour to exchange chloride 
anions with aurate. The sample was then loaded onto the grid as described above.  
 
Determination of the minimum bactericidal concentration (MBC) 
The bacteria used were E. coli (ATCC 29425) and S. aureus (ATCC 6538). After inoculation of 
10 mL of 0.3 mM pH 7.4 phosphate buffer, the bacteria were cultured overnight in an incubator-
shaker at 37 °C. They were then pelletized by centrifugation and the broth was decanted. 10 mL 
of phosphate solution was then used to resuspend the pellet. The bacteria were again pelletized 
by centrifugation. This process of resuspension and centrifugation was repeated twice more. For 
S. aureus, a suspension with an optical density of 0.3 at 600 nm, corresponding to 107 CFU/mL 
was prepared. For E. coli, a suspension with an optical density of 0.2 at 600 nm, corresponding 
to 108 CFU/mL was prepared. These stock solutions were then diluted to ~2 x 105 CFU/mL.  
Samples for testing were prepared at the highest concentration for testing in 0.3 mM pH 
7.4 phosphate buffer and serial two-fold dilutions were performed to achieve lower 
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concentrations. All molecules and assemblies were sterilized by irradiation with UV light in a 
UV light cabinet for 30 minutes prior to testing. Tests were performed in 96 well plates. Sample 
wells contained 100 μL of the sample material in phosphate buffer and 100 μL of the bacterial 
suspension at 105 CFU/mL. Control wells contained 100 μL of phosphate buffer and 100 μL of 
the bacterial suspension at 105 CFU/mL. The phosphate buffer was also tested for sterility. 
Samples and controls were measured in triplicate. The wells were mixed for 4 hours at ambient 
temperature using a Tecan infinite M1000 Pro (Tecan Trading AG, Switzerland) plate reader. 
The suspensions were then diluted by adding 100 μL of the well contents into 9.9 mL of 
phosphate buffer to give a resulting bacterial concentration of approximately 103 CFU/mL. 100 
μL of this suspension was then pour plated in nutrient agar and incubated overnight at 37 °C. The 
nutrient agar was prepared by dissolving 25 g of LB broth (Miller’s modification) (Alfa Aesar, 
Reston, United States) and 15 g of Agar Powder (C12H18O9)x (Alfa Aesar, Reston, United States) 
in 1 L of hot water (85°C). The following day the bacterial colonies were counted. The MBC 
was determined as the concentration where no bacterial colonies were observed (>99% reduction 
in viability, based on 102 CFUs plated). A summary of the concentrations tested and their 
corresponding results are includes in Tables S1 and S2. 
 
Hemolysis assay 
The hemolytic activity of the nanocarriers was determined using sterile defibrinated sheep’s 
blood (Cedarlane Labs, Burlington Ontario, Canada). The blood was pelletized by centrifuging 1 
mL of the blood and washing the pellet four times with 0.9 % saline. The pellet was resuspended 
in 1 mL of a phosphate buffered saline (PBS) consisting of 0.32 mM NaH2PO4 and 140.40 mM 
NaCl maintained at a pH of 7.4 to create the red blood cell (RBC) suspension. A concentrated 
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solution of the micelles was diluted with 750 μL of the PBS to the highest concentration for the 
assay. The micelle solutions were diluted two-fold serially with PBS to achieve the desired 
concentrations. To the micelle solutions 25 µL of the RBC suspension was added. A negative 
control of 25 µL	of the RBC suspension in 1000 µL of the PBS and a positive control of 25 µL of 
the RBC suspension in 1000 µL purified water. Nanocarrier background controls were made 
consisting of the same concentration of the nanocarrier in PBS to eliminate absorbance or 
scattering contributions from the nanocarriers themselves. The samples were incubated at room 
temperature for 2 hours and afterward the samples were centrifuged to re-pelletize the blood 
cells. 200 µL of the supernatant of each sample and control were placed into wells in a 96 well 
plate and the absorbance (A) at 540 nm was measured. The percent hemolysis was determined 
with the following equation: 





500 μL of a solution of tetracycline (0.5 mg/mL in CHCl3) was used to dissolve either MeO-
BCP or Bu3P-BCP (5 mg). With rapid stirring 2 mL of purified water was added and stirring 
was continued overnight at 30 °C. The sample was covered with aluminum foil to allow 
evaporation of CHCl3 while at the same time preventing exposure to ambient light. The resulting 
suspension was then introduced into a MicrosepTM Advance Centrifugal Device with a 10 kg/mol 
MWCO (Pall Life Sciences) and the solvent was reduced to 1/5 its initial volume. The 
concentrated suspension was diluted to 2 mL of purified water, and centrifugation was performed 
again. The filtrate was combined and the concentration of tetracycline in the filtrate was 
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measured by UV-visible spectroscopy (e = 14,075 M-1cm-1 in water at 363 nm) in order to 
determine the encapsulation efficiency (EE) of tetracycline as: 
EE = 
Mass of Drug in Particles
Mass of Drug Added
×100% 
The drug loading content (DLC) of the assemblies could then be calculated as: 
DLC=	 Mass of Drug in Particles
Mass of Loaded Particles
×100	% 
 
Tetracycline release study 
Assemblies containing encapsulated tetracycline were prepared as described above except that 
0.3 mM, pH 7.2 phosphate buffer was used.  A volume of 2 mL each of tetracycline-loaded 
MeO-BCP or Bu3P-BCP micelles was then placed on a wrist-action shaker. At measurement 
time points, centrifugal ultrafiltration was performed as described above to separate released 
tetracycline from the suspension and the concentrated suspension was diluted again to 2 mL with 
the phosphate buffer. The absorbance of the filtrate was measured and the concentration of 
tetracycline in the filtrate was determined based on an e = 14,075 M-1cm-1 in the same buffer at 
363 nm. 
 
Results and Discussion 
Synthesis of PEO-b-PCL copolymers  
PEO-b-PCL copolymers were selected because of their established biocompatibility and low 
toxicity in drug delivery applications.39 An azide terminal group on the PEO was selected for the 
conjugation of the phosphonium moiety via a copper-assisted azide-alkyne cycloaddition 
(CuAAC). Methoxy- and azide-terminated PEO-b-PCL copolymers, MeO-BCP and N3-BCP 
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respectively, were synthesized according to our previously reported procedure.38 MeO-PEO or 
N3-PEO were used as macroinitiators to polymerize caprolactone in toluene using 
methanesulfonic acid (MSA) as a catalyst (Scheme 1).38 This method yields copolymers with 
very low molar mass dispersity (Ð). Low Ð is important for good control over the morphology of 
the self-assemblies.40 From previous research it is known that a mass ratio of PCL:PEO of 1.3:1 
yields micellar nanocarriers.41 Therefore, using a PEO macroinitiator of ~2000 g/mol, a degree 
of polymerization (DP) of ~24 caprolactone repeat units was targeted. The resulting block 
copolymers were characterized by NMR spectroscopy and SEC. 1H NMR spectroscopy 
confirmed that the DPs were ~24 for each of MeO-BCP and N3-BCP, corresponding to an Mn of 
~4700 g/mol (Figure S1-S2). By SEC relative to PEO standards, MeO-BCP had a number 
average molar mass (Mn) of 5750 g/mol and Ð of 1.11, while N3-BCP had an Mn of 5950 g/mol 
and Ð of 1.12 (Figure S3). The differences in Mn of these copolymers measured by SEC likely 
arose from their different terminal groups. 
 
Scheme 1. Synthesis of MeO-BCP and N3-BCP. 
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Synthesis of alkyne-functionalized phosphonium salts 
Alkyne-functionalized phosphonium centres were required for conjugation to N3-BCP. The 
lengths of the alkyl chains on phosphonium and ammonium salts are known to affect the 
antibacterial activity of the small molecules,32 so it was desirable to explore this in the context of 
phosphonium-functionalized polymer assemblies. Initial attempts to prepare the alkyne-
functionalized phosphonium salts by reaction of trialkylphosphines with propargyl bromide 
resulted in complex and inseparable product mixtures. This is due to side reactivity of the 
phosphonium salt with the unreacted phosphine.42 While addition of hydrobromic acid to the 
reaction reduced the number of products, isolation of the desired product remained elusive. On 
the other hand, use of 5-chloro-1-pentyne led to the conversion of triethylphosphine and tri-n-
butylphosphine into single products Et3P-yne and Bu3P-yne, respectively (Scheme 2). The 
synthesis of Oct3P-yne yielded a mixture of products and silica gel column chromatography was 
used for purification. This was attributed to the extended heating time required to convert the 
starting material into product as this phosphine is more sterically hindered. In each case, the pure 
product was characterized by multinuclear magnetic resonance spectroscopy and high resolution 
mass spectrometry. The products showed characteristic peaks corresponding to both the alkyne 
and alkyl chains around the phosphonium cation (Figure 2). 
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Scheme 2. Synthesis of the phosphonium salts and the phosphonium capped polymers. 
 
 
Figure 2. 1H NMR spectra (CDCl3, 400 MHz) of the phosphonium salts with selected peaks 
labeled. 
 



















Attachment of the phosphonium salts to N3-BCP was achieved using CuAAC in 4:1 H2O:THF 
with CuCl2 and sodium ascorbate to afford Et3P-BCP, Bu3P-BCP, and Oct3P-BCP (Scheme 2). 
Due to the onwards use of the polymer in anti-bacterial testing it was imperative that any residual 
copper be removed from the functionalized materials. The reaction mixtures were therefore 
dialyzed against large volumes of 0.5 M NaCl solution, followed by water. The dialysis against 
aqueous NaCl was important to ensure that the phosphonium counterion remained chloride as 
there are reports in the literature that ascorbate may show antibacterial activity, thus we needed 
to preclude the chance of anion exchange.43 As shown in Figure 3 and S9-S10, IR spectra of the 
initial N3-BCP showed strong azide stretches at 2100 cm-1, whereas this peak was no longer 
detectable beyond the background noise for the conjugated phosphonium products. Integration of 
the 1H NMR signals corresponding to the methyl protons on the phosphonium groups relative to 
the terminal methylene group of the PEO block adjacent to the first repeat unit of the PCL block 
were consistent with complete conversion of the azides (Figure S11-S13). Peaks characteristic of 
the proton on the triazole ring were also observed in the 1H NMR spectra of the phosphonium 
functionalized polymers.  
 




Figure 3. ATR-IR spectra of the starting N3-BCP (blue spectrum) and Bu3P-BCP (orange 
spectrum) showing the disappearance of the azide stretch following the CuAAC reaction. 
 
Micelle preparation and characterization 
The micelles were prepared from MeO-BCP, Et3P-BCP, Bu3P-BCP, and Oct3P-BCP by 
nanoprecipitation of a polymer solution in THF into water, which is a selective solvent for the 
PEO block of the copolymers. The rapid decrease in solubility of the PCL block in the solvent 
mixture causes the polymers to precipitate into nano-sized cores surrounded by PEO. Figures 4 
A-D show representative TEM images of the resulting assemblies. Assemblies prepared from the 
phosphonium cation-capped polymers were stained using auric acid (Figure 4B-D). In this case, 
the aurate can undergo anion exchange to bind to the positively charged phosphonium ion.44 In 
each case, solid spherical particles were observed. The sub-50 nm diameters of the MeO-BCP, 
Et3P-BCP, and Bu3P-BCP assemblies suggests that they were largely true micellar structures, 
whereas some larger 50 – 100 nm assemblies were observed for Oct3P-BCP, suggesting that 
some compound micelles or aggregates of micelles were also present. The Oct3P-yne is not 
soluble in water and so installation of this hydrophobic end group on the hydrophilic block may 




Figure 4. A – D) TEM micrographs of the assemblies prepared by nanoprecipitation (scale bar 
represents 100 nm): A) MeO-BCP micelles, B) Et3P-BCP micelles, C) Bu3P-BCP micelles, D) 
Oct3P-BCP assemblies. All Alk3P-BCP samples (B-D) were stained with auric acid. E) Volume 
distributions of the assembly diameters measured by DLS. 
 
As shown in Figure 4E and Table 1, the hydrodynamic diameters measured by dynamic 





























micelles had a Z-average diameter of ~30 nm, while Et3P-BCP, and Bu3P-BCP micelles had 
similar Z-average diameters of 40 – 45 nm. The larger diameters of these phosphonium-
functionalized micelles relative to the MeO-BCP micelles may result from repulsive 
electrostatic interactions between the peripheral phosphoniums. Oct3P-BCP assemblies had a 
larger Z-average diameter of 59 nm due to the presence of compound micelles or aggregates as 
noted above. ζ-potentials of the micelles were also measured. MeO-BCP micelles had a ζ-
potential of -23 mV. This is typical for assemblies with PEO coronas.45 On the other hand, all of 
the phosphonium-functionalized micelles had positive ζ-potentials and these ranged from 19 to 
30 mV. This confirms that the phosphonium cations reside on the surface of the micelles. 
Interestingly, the value of the ζ-potential increased with the length of the alkyl chain on the 
phosphonium center. This was somewhat unexpected as the more hydrophobic phosphonium 
cations could be buried within the PEO corona. However, the results reveal that this may not be 
the case and the cause of the observed trend in not clear at this time.  
 
Table 1. Hydrodynamic diameters and ζ-potentials measured for the polymer assemblies by 







MeO-BCP micelles 29.5 ± 0.8 0.122 ± 0.027 -23.2 ± 5.2 
Et3P-BCP micelles 45.0 ± 2.5 0.072 ± 0.003 19.0 ± 2.4 
Bu3P-BCP micelles 39.6 ± 3.7 0.213 ± 0.025 26.8 ± 7.7 
Oct3P-BCP assemblies 58.9 ± 2.8 0.110 ± 0.020 29.7 ± 0.5 
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Antibacterial properties of phosphonium-functionalized assemblies 
The antibacterial efficacies of the phosphonium-functionalized micelles and their corresponding 
small molecule phosphonium salts were evaluated by measuring their minimum bactericidal 
concentrations (MBC). The MBC is the concentration required to kill 99% of bacteria in the 
assay. This assay involved inoculating varying concentrations of the assemblies or small 
molecules in pH 7.4 phosphate buffer with a bacterial suspension containing 105 colony forming 
units (CFU)/mL of either Gram-negative E. coli (ATCC 29425) or Gram-positive S. aureus 
(ATCC 6538). The inoculated samples were incubated at 37 °C for 4 hours, then the resulting 
suspensions were plated on agar, incubated overnight and then the bacterial colonies were 
counted. The percent reduction, and thus MBC, was calculated by comparing the number of 
colonies counted after incubation with the sample compared to those of bacteria exposed to only 
phosphate buffer with no polymer or small molecule added.  
As shown in Table 2, the small molecule phosphonium cations had relatively high MBC 
values against both E. coli and S. aureus. It was not possible to test Oct3P-yne due to its poor 
aqueous solubility, but Et3P-yne had a MBC greater than 45 mM, the highest concentration 
tested, against S. aureus than E. coli. Bu3P-yne was more active, with MBC values of 4.1 mM 
and 33 mM for S. aureus than E. coli, respectively. MeO-BCP micelles were also studied and 
the MBC was found to be greater than 1.1 mM in terms of polymer chain concentration for both 
strains of bacteria, the highest concentration tested. Thus, the block copolymers themselves are 
not antibacterial. On the other hand, the phosphonium-functionalized assemblies all had much 
lower MBCs than the small molecules, demonstrating the importance of having a multivalent 
display of cations. Interestingly there was no observed difference in MBC between the Et3P-
BCP micelles and Bu3P-BCP micelles with S. aureus (0.13 mM for both systems), but there was 
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with E. coli (0.26 mM and 0.13 mM, respectively). The Oct3P-BCP assemblies had the greatest 
activity against S. aureus with an MBC of 0.031 mM, while they had the highest MBC of the 
phosphonium-functionalized assemblies against E. coli at 0.49 mM.  
Table 2. MBC values for the phosphonium salts and phosphonium-functionalized assemblies 
against S. aureus and E. coli. For the block copolymers, the concentrations correspond to the 
concentrations of polymer chains, and thus the concentration of the terminal phosphonium 
groups. 






Et3P-yne > 45 > 45 
Bu3P-yne 4.1 32.8 
MeO-BCP 
micelles 











With the exception of Bu3P-BCP micelles, higher MBC values were found for E. coli.  
The lower efficacy against E. coli was expected based on previous research, and can likely be 
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attributed to differences in the cell wall structures of Gram-positive and Gram-negative 
bacteria.46 Gram-positive bacteria such as S. aureus have a plasma membrane surrounded by a 
periplasmic space and a peptidoglycan layer, whereas Gram-negative bacteria such as E. coli 
have an additional outer membrane surrounding the peptidoglycan layer. The mode of action of 
monocationic and polycationic biocides is generally accepted to include the following processes: 
1) Biocide adsorption to the cell surface, 2) biocide diffusion through the cell wall, 3) adsorption 
to the cytoplasmic membrane, 4) cytoplasmic membrane disruption, and 5) loss of cytoplasmic 
components, resulting in cell death.31 Gram-negative bacteria have an additional barrier through 
which the biocide must diffuse, and disrupt, which may explain why higher concentrations of 
micelles were generally required to kill E. coli.   
It was also noted that different trends with respect to alkyl chain length were observed for 
the different strains of bacteria as Oct3P-BCP micelles had the lowest MBC for S. aureus, 
whereas Bu3P-BCP micelles had the lowest MBC for E. coli. While phosphonium groups with 
longer alkyl chains have been previously demonstrated to show greater antibacterial activity in 
general34 there is also data to suggest that the relationship between alkyl chain length and 
antibacterial efficacy is not linear and in some cases lower activity has been observed with 
increased alkyl chain length.47 As hydrophilic cationic groups promote attachment to bacterial 
membrane and hydrophobic alkyl chains insert into membranes to disrupt them, the 
hydrophilicity and hydrophobicity must be balanced to match the requirements of the different 
bacterial membranes. 48 It is also possible that the larger size of the Oct3P-BCP assemblies plays 
a role. The larger size of the individual assemblies results in fewer particles for a given 
polymer/phosphonium concentration and thus fewer assemblies and less surface area to interact 
with the bacteria.49 In comparing the small molecule cationic biocides with polycationic 
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biocides, the small molecules typically have higher rates of diffusion through the cell wall, while 
the multivalent nature of polycationic biocides increases the adsorption to the cell surface and the 
cytoplasmic membrane, often leading to increased rates and occurrences of cytoplasmic 
membrane disruption.31  
The phosphonium-functionalized assemblies can also be compared with other 
antibacterial polymer assemblies. For example, Du and co-workers demonstrated the preparation 
of silver nanoparticle-decorated micelles and vesicles with antibacterial activity.21 These 
assemblies had a low MBC of 8.69 x 10-2 mM of Ag. However, it is unclear whether the activity 
of the system arose from nano-silver associated with the micelles or dissociated Ag+ ions 
released into solution that were not associated with the micellar corona.21 The mechanism of 
bacterial killing by nano-silver, while controversial,50 is also different and is thought to involve 
the inactivation of the bacterial DNA and ribosomes by silver ions.51,52 Later, the same group 
reported the preparation of antibacterial nanoassemblies composed of poly[2-(2-
methoxyethoxy)ethyl methacrylate]20-block-poly[2-(tert-butylaminoethyl) methacrylate]20.26 The 
polyamine block ionizes in solution to give positively charged particles. Vesicles prepared from 
the above polymer were reported to have MBC values of 0.63 mM of amine against both E. coli 
and S. aureus.26 Later, multicompartment polymer vesicles prepared from the same polymers 
were reported to have improved antibacterial efficacy with MBC values of 0.1 mg/mL or 1.27 x 
10-2 mM of amine, a value lower than their measured minimum inhibitory concentration (MIC) 
values for the same material.27 As the MIC corresponds to the concentration required to inhibit 
bacterial growth but not necessary kill the bacteria, MIC values are not generally expected to be 
higher than MBC values. However, this discrepancy may be due to differences in the testing 
methods. Du and coworkers also reported that low MIC values in the μM range could be 
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achieved against E. coli and  S. aureus using polypeptides as the hydrophilic block of a vesicle 
forming polymeric amphiphile.53  
 
Hemolysis of red blood cells  
A challenge often encountered with membrane-active antibacterial agents is that in addition to 
lysing bacterial cell membranes, they can also lyse the membranes of red blood cells, resulting in 
non-specific toxicity. Therefore, to evaluate the potential of the phosphonium-functionalized 
micelles to lyse red blood cells, a hemolysis assay was performed. Briefly, following a 
previously reported procedure,54 red blood cells were obtained from defibrinated sheep blood 
and were incubated with MeO-BCP, Et3P-BCP, Bu3P-BCP, Oct3P-BCP micelles in PBS for 2 
hours. As a positive control, red blood cells were suspended in deionized water, resulting in the 
immediate lysis of the cells. The absorbance of the supernatant at 540 nm after pelletization of 
the intact blood cells was measured. As shown in Figure 5, only 0.53 mM of Et3P-BCP micelles 
exhibited any hemolytic activity, with 7% hemolysis observed. Interestingly, this particular 
system was the least active of the 3 systems against both strains of bacteria, so this result was 
unexpected. While there is not a complete understanding of all the factors influencing selectivity 
for eukaryotic and prokaryotic membranes,46 it is likely that the particular hydrophilic-
hydrophobic balance of the Et3P-BCP micelles results in its higher activity against red blood cell 
membranes.55 Nevertheless, the overall results suggest that the phosphonium-functionalized 
micelles have good potential to selectively kill bacteria. While further studies would be required 
to elucidate the in vitro and in vivo toxicity, previous studies have shown that phosphonium 
compounds can exhibit low in vitro,36,56 and in vivo56 toxicity. 
 26 
 
Figure 5. Hemolysis of red blood cells from defribinated sheep blood. 0% hemolysis 
corresponds to the control of red blood cells in PBS while 100% hemolysis corresponds to the 
positive control of red blood cells in purified water. 
 
Encapsulation and release of tetracycline 
The antibacterial efficacy of the phosphonium-functionalized assemblies can potentially be 
enhanced through encapsulation of a small molecule antibiotic that acts through a mechanism 
other than membrane disruption, thereby targeting multiple different stages of the infection 
process. Such an approach has not been explored in the context of antibacterial polymer 
assemblies to the best of our knowledge.  Tetracycline (Figure 6) was chosen as the antibiotic as 
it is widely used and is hydrophobic, resulting in low aqueous solubility and the possibility to 
encapsulate it in the hydrophobic PCL cores of the micelles. Tetracycline acts by binding to the 
bacterial ribosome and preventing the production of new proteins.57 It was encapsulated in the 
micelles through co-dissolution with the polymer in CHCl3, followed by the addition of water 
with rapid stirring and heating at 30 °C overnight to evaporate the CHCl3. Unencapsulated drug 
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was then removed by centrifugal ultrafiltration (Figure S14). This procedure was performed for 
both MeO-BCP and Bu3P-BCP in order to determine the effect of the phosphonium moieties on 
the drug loading and release. This afforded assemblies with diameters of 65 ± 5 nm for MeO-
BCP as measured by DLS (Figure S15). The amount of drug loaded into the assemblies was 
determined as the difference between the drug added during assembly and the unencapsulated 
drug removed by ultrafiltration, which was determined by UV-vis spectroscopy. The EE and 
DLC were determined to be 31 ± 7 % and 2.0 ± 0.2 % for MeO-BCP and, 42 ± 3 % and 3.1 ± 
0.3 % for Bu3P-BCP respectively. The higher EE and DLC observed in the Bu3P-BCP system 
may result from ionic interactions between the anionic tetracycline and the cationic phosphonium 
ions on the micelles.  
 
Figure 6. Release profiles of tetracycline from MeO-BCP micelles and Bu3P-BCP micelles. 
Inset: tetracycline structure 
 
The release rate of tetracycline from the MeO-BCP and Bu3P-BCP micelles was then 
studied by incubating the drug-loaded micelles at 37 °C in pH 7.2 phosphate buffer. At each time 
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point, centrifugal ultrafiltration was used to separate the micelles from the released drug and the 
concentration of the released drug was measured. As shown in Figure 6, all of the encapsulated 
tetracycline was released from the MeO-BCP micelles in ~5 hours. The release of tetracycline 
was somewhat slower from the Bu3P-BCP micelles, with ~70% of the drug being released over 
the first 5 h and 100% release over 24 h. The differences in release rates between the two 
systems is likely due to the presence of the phosphonium end cap. Upon release from the 
hydrophobic micelle core into the phosphate buffer, tetracycline’s vinylogous carboxylic acid 
may become deprotonated and undergo ionic interactions with the phosphonium cations on the 
surfaces of the micelle, thereby slowing its release. 
 Antibacterial assays with E. coli were performed to examine the added effect of the 
tetracycline in the micelle core. It was found that at the tetracycline loadings described above, 
the activity of the Bu3P-BCP micelles was dominated by the phosphonium groups and the same 
MBC value was determined. No activity was observed for tetracycline-loaded MeO-BCP 
micelles over a 4 hour incubation at a concentration of 0.26 mM of polymer. This can be 
attributed to the bacteriostatic effects of tetracycline. On the time scale of the experiment, the 
tetracycline would not kill bacteria but instead just inhibit its ability to produce new proteins.58 
Thus, these experiments were not able to reveal an additive or synergistic effect of the drug and 
phosphonium on the bacteria. However, this does not preclude the possibility of observing one in 
vivo where the released drug could exhibit significantly different biodistribution than the 
assemblies and may reach sites not accessible to the polymer assemblies. Further studies will be 




In conclusion, this study demonstrated the synthesis and self-assembly of three new 
phosphonium-functionalized PEO-b-PCL copolymers with varying alkyl chain lengths on the 
phosphonium. Et3P-BCP, Bu3P-BCP, and the control MeO-BCP self-assembled into micelles 
with diameters less than 50 nm, while Oct3P-BCP formed larger micelles or aggregates. All of 
the phosphonium-functionalized assemblies had positive z-potentials, whereas the MeO-BCP 
micelles had a negative z-potentials. Despite relatively low loadings of the antibacterial 
component (only a single phosphonium unit per polymer chain), sub-mM MBC values were 
obtained against both E. coli and S. aureus and the activities of the different systems depended 
on the bacterial stain due to differences in their cell wall structures. In comparing the MBC 
values for the assemblies with those of the corresponding phosphonium small molecules, the 
assemblies were much more effective in killing bacteria, presumably due to their multivalent 
interactions with the bacteria. The low loadings of the phosphonium groups on the assemblies 
also allowed then to exhibit excellent hemolytic stability, with only the highest concentration of 
Et3P-BCP micelles showing any hemolytic activity, above the MBC for both S. aureus and E. 
coli. It was also demonstrated that the intrinsically antibacterial Bu3P-BCP micelles could 
encapsulate and release tetracycline, providing the potential for an orthogonal mechanism of 
attack against bacteria during the infection process. Future work will involve further 
optimization of the system and as well as further exploration of the multifunctional capabilities 
of these micelles. 
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